Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/127997
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Domínguez Sosa, Maria Sandra | en_US |
dc.contributor.author | Cabrera Ramírez, María Soledad | en_US |
dc.contributor.author | Marrero Ramos, Miriam Del Carmen | en_US |
dc.contributor.author | Dávila Quintana, Carmen Delia | en_US |
dc.contributor.author | Cabrera López, Carlos | en_US |
dc.contributor.author | Carrillo Díaz, Teresa | en_US |
dc.contributor.author | Benítez Del Rosario, Jesús | en_US |
dc.date.accessioned | 2023-12-19T14:28:25Z | - |
dc.date.available | 2023-12-19T14:28:25Z | - |
dc.date.issued | 2023 | en_US |
dc.identifier.issn | 2227-9059 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/127997 | - |
dc.description.abstract | The aim of this study was to evaluate the efficacy of mepolizumab in patients affected by chronic rhinosinusitis with nasal polyps (CRSwNP) in real-life. A single-center retrospective observational study was conducted on severe CRSwNP patients treated with mepolizumab. Nasal endoscopic polyp score (NPS), visual analogue scale (VAS) symptom score, sinonasal outcome test (SNOT-22), asthma control test (ACT) score, fractional exhaled nitric oxide (FeNO), eosinophils blood cells and prednisone intake were assessed at baseline and after 6 months. A total of 55 patients were included; 49 patients (89%) presented with asthma; aspirin exacerbated respiratory disease (AERD) in 28 patients (51%). A statistically significant decrease in the SNOT-22 score was observed (median difference −63; 95% CI: −68; −58; p < 0.001) with median t0 76 and IQR (61;90) to t6 10 (5;15). A reduction in NPS, median t0 NPS 4; (IQR:4;6), median t6 NPS 1; (IQR:0;1) p < 0.001, was greater in patients with AERD. The median baseline VAS score was 6 (IQR:6;7) and the differences between t0 and t6 were statistically significant p < 0.001. Significant changes in blood eosinophils cells, median t0 500 cell/mcl (IQR:340;830), median t6 97 cell/mcl (IQR:60;160) p < 0.001, were greater in patients with AERD. Mepolizumab treatment effects have been demonstrated with significantly reduced symptoms, polyp scores, blood eosinophils and systemic corticosteroid use, resulting in an increased health-related quality of life in patients with severe CRSwNP, regardless of the presence or absence of asthma or AERD. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Biomedicines | en_US |
dc.source | Biomedicines [2227-9059], v. 11(2):485 (Febrero 2023) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 3209 Farmacología | en_US |
dc.subject | 320701 Alergias | en_US |
dc.subject.other | Chronic rhinosinusitis | en_US |
dc.subject.other | Nasal polyps | en_US |
dc.subject.other | Mepolizumab | en_US |
dc.subject.other | Aspirin exacerbated respiratory disease | en_US |
dc.subject.other | SNOT-22 | en_US |
dc.subject.other | Nasal polyp score | en_US |
dc.title | Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps | en_US |
dc.type | info:eu-repo/semantics/Article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.3390/biomedicines11020485 | en_US |
dc.identifier.scopus | 2-s2.0-85148882192 | - |
dc.identifier.isi | WOS:000938379700001 | - |
dc.contributor.orcid | 0000-0001-9445-4537 | - |
dc.contributor.orcid | 0000-0001-6164-107X | - |
dc.contributor.orcid | 0000-0002-6679-0557 | - |
dc.contributor.orcid | 0000-0002-4608-1040 | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.contributor.orcid | #NODATA# | - |
dc.identifier.issue | 2 | - |
dc.relation.volume | 11 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 15 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Febrero 2023 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 0,962 | |
dc.description.jcr | 3,9 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q1 | |
dc.description.esci | ESCI | |
dc.description.miaricds | 10,4 | |
item.grantfulltext | open | - |
item.fulltext | Con texto completo | - |
crisitem.author.dept | Departamento de Métodos Cuantitativos en Economía y Gestión | - |
crisitem.author.dept | GIR IUIBS: Patología y Tecnología médica | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.dept | GIR SIANI: Ingeniería biomédica aplicada a estimulación neural y sensorial | - |
crisitem.author.dept | IU Sistemas Inteligentes y Aplicaciones Numéricas | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-4608-1040 | - |
crisitem.author.orcid | 0000-0002-3047-8908 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU Sistemas Inteligentes y Aplicaciones Numéricas | - |
crisitem.author.fullName | Domínguez Sosa, Maria Sandra | - |
crisitem.author.fullName | Marrero Ramos, Miriam Del Carmen | - |
crisitem.author.fullName | Dávila Quintana, Carmen Delia | - |
crisitem.author.fullName | Carrillo Díaz, Teresa | - |
crisitem.author.fullName | Benítez Del Rosario, Jesús | - |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
25
checked on Mar 30, 2025
WEB OF SCIENCETM
Citations
21
checked on Mar 30, 2025
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.